Back to discover
Disease

Eye Neoplasms

Emerging research
MeSHEye Neoplasms
2
Publications
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Carmustineapproved

Approval — Carmustine is indicated n adults in the following malignant neoplasms as a single ag… (2018)

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2018emaApproval — Carmustine· Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma). source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
19982024
Major themes2
  • Eye Neoplasms1
  • Molecular Targeted Therapy1
Leading journals2
  • Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)1
  • Cancer1
Leading researchers6
  • Chang AE1
  • Demirci H1
  • Honavar SG1
  • Karnell LH1
  • Menck HR1
  • Sen M1
Affiliations (unnormalised)3
  • Centre for Sight Eye Hospital1
  • Kellogg Eye Center1
  • University of Michigan Medical Center1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Tumors or cancer of the EYE.

Identifiers
MeSHEye Neoplasms
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.